Part I. Principles of Psychopharmacology
Section Editor: Robert C. Malenka, M.D., Ph.D.
|
| Chapter 1. Neurotransmitters, Receptors, Signal Transduction, and Second Messengers in Psychiatric Disorders |
| Chapter 2. Basic Principles of Molecular Biology and Genomics |
| Chapter 3. Genetics and Genomics |
| Chapter 4. Chemical Neuroanatomy of the Primate Brain |
| Chapter 5. Electrophysiology |
| Chapter 6. Animal Models |
| Chapter 7. Psychoneuroendocrinology |
| Chapter 8. Principles of Pharmacokinetics and Pharmacodynamics |
| Chapter 9. Brain–Immune System Interactions: Relevance to the Pathophysiology and Treatment of Neuropsychiatric Disorders |
| Chapter 10. Brain Imaging in Psychopharmacology |
| Chapter 11. Statistics, Placebo Response, and Clinical Trial Design in Psychopharmacology |
Part II. Classes of Psychiatric Treatments: Animal and Human Pharmacology
Section Editors: K. Ranga Rama Krishnan, M.D., and Dennis S. Charney, M.D.
|
| Antidepressants and Anxiolytics |
| Chapter 12. Tricyclic and Tetracyclic Drugs |
| Chapter 13. Fluoxetine |
| Chapter 14. Sertraline |
| Chapter 15. Paroxetine |
| Chapter 16. Fluvoxamine |
| Chapter 17. Citalopram and S-Citalopram |
| Chapter 18. Monoamine Oxidase Inhibitors |
| Chapter 19. Trazodone and Nefazodone |
| Chapter 20. Bupropion |
| Chapter 21. Mirtazapine |
| Chapter 22. Venlafaxine and Desvenlafaxine |
| Chapter 23. Duloxetine and Milnacipran |
| Chapter 24. Benzodiazepines |
| Chapter 25. Buspirone and Gepirone |
| Chapter 26. Putative New-Generation Antidepressants |
| Antipsychotics |
| Chapter 27. Classic Antipsychotic Medications |
| Chapter 28. Clozapine |
| Chapter 29. Olanzapine |
| Chapter 30. Quetiapine |
| Chapter 31. Aripiprazole |
| Chapter 32. Risperidone and Paliperidone |
| Chapter 33. Ziprasidone |
| Chapter 34. Drugs to Treat Extrapyramidal Side Effects |
| Drugs for Treatment of Bipolar Disorder |
| Chapter 35. Lithium |
| Chapter 36. Valproate |
| Chapter 37. Carbamazepine and Oxcarbazepine |
| Chapter 38. Gabapentin and Pregabalin |
| Chapter 39. Lamotrigine |
| Chapter 40. Topiramate |
| Other Agents |
| Chapter 41. Cognitive Enhancers |
| Chapter 42. Sedative-Hypnotics |
| Chapter 43. Psychostimulants and Wakefulness-Promoting Agents |
| Chapter 44. Electroconvulsive Therapy |
Part III. Clinical Psychobiology and Psychiatric Syndromes
Section Editor: David J. Kupfer, M.D.
|
| Chapter 45. Neurobiology of Mood Disorders |
| Chapter 46. Neurobiology of Schizophrenia |
| Chapter 47. Neurobiology of Anxiety Disorders |
| Chapter 48. Neurobiology of Alzheimer's Disease |
| Chapter 49. Neurobiology of Substance Abuse and Addiction |
| Chapter 50. Neurobiology of Eating Disorders |
| Chapter 51. Neurobiology of Personality Disorders |
| Chapter 52. Neurobiology of Childhood Disorders |
Part IV. Psychopharmacological Treatment
Section Editor: David L. Dunner, M.D.
|
| Chapter 53. Treatment of Depression |
| Chapter 54. Treatment of Bipolar Disorder |
| Chapter 55. Treatment of Schizophrenia |
| Chapter 56. Treatment of Anxiety Disorders |
| Chapter 57. Treatment of Agitation and Aggression in the Elderly |
| Chapter 58. Treatment of Substance-Related Disorders |
| Chapter 59. Treatment of Eating Disorders |
| Chapter 60. Treatment of Insomnia |
| Chapter 61. Treatment of Personality Disorders |
| Chapter 62. Treatment of Psychiatric Emergencies |
| Chapter 63. Treatment of Child and Adolescent Disorders |
| Chapter 64. Psychopharmacology During Pregnancy and Lactation |
| Chapter 65. Treatment During Late Life |
| Chapter 66. Treatment of Chronic Pain Syndromes |
Part V. Ethical Issues
|
| Chapter 67. Ethical Considerations in Psychopharmacological Treatment and Research |